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SUMMARY 
• The insulin receptor is a member of the largely ex- 
panding family of plasma membrane receptors. In general, 
ligand binding induces receptor dimerization leading to acti- 
vation and tyrosine phosphorylation of the cytoplasmic cata- 
lytic domain of the receptor. Activation of receptor tyrosine 
kinases leads to several cellular responses like proliferation, 
differentitation and survival. The insulin receptor family 
distinghuishesfrom the other receptor tyrosine kinases in that 
it also mediates a metabolic response like stimulation of glu- 
cose uptake and glycogen synthesis. In this review the gen- 
eral principles of signaling by receptor tyrosine kinases are 
discussed. Besides, we point out the signaling pathways used 
by the insulin receptor itself. 
INTRODUCTION 
• Many cellular processes in eukaryotes such as prolif- 
eration, differentiation and apoptosis are regulated by exter- 
nal signals. An important group of external signals is repre- 
sented by polypeptide growth factors. Some polypeptide growth 
factors bind with high affinity to a group of cell surface recep- 
tors with intrinsic tyrosine kinase (trk) activity, the receptor 
tyrosine kinases (Rtrk). Ligand binding to these receptors leads 
to activation of the Rtrk and of a whole array of early signal- 
ing intermediates, such as phospholipases, various serine/threo- 
nine kinases, small GTP-binding proteins, non-Rtrk, and pro- 
tein tyrosine phosphatases. The activation of early signaling 
intermediates precedes the activation of several phosphoryla- 
tion cascades, leading to stimulation of gene expression, 
changes in intracellular calcium levels, and the generation of 
phospholipid metabolites. Despite striking similarities in 
postreceptor signaling, Rtrk often exert their own specific ef- 
fects. These pleiotropic responses can be partially explained 
by structural characteristics of the Rtrk, and tissue-specific 
expression of their ligands. Alternatively, the array of signal- 
ing intermediates activated by a specific Rtrk in a certain tis- 
sue may contribute to the nature of the response. In this re- 
view, the activation of early signaling pathways by Rtrk, and 
the occurrence of cross-talk between signaling pathways are 
discussed. 
STRUCTURAL AND FUNCTIONAL 
CHARACTERISTICS OF RECEPTOR TYROSIHE 
KIHASES 
•        Overall structure 
All Rtrk are transmembrane proteins (1,2). The extracellular 
domain is the most distinctive feature in Rtrk. It contains a 
characteristic array of structural motifs, such as cysteine-rich 
stretches, and sequences homologous to immunoglobulin or 
fibronectin type III. The extracellular domain is involved in 
ligand binding and is often modified by N-linked glycosylation 
and O-linked sugars. The single membrane spanning region 
is composed of a stretch of 20-25 generally hydrophobic amino 
acids, followed by several basic residues that represent the stop 
transfer signal anchoring the protein in the plasma membrane. 
The cytosolic domain contains a highly conserved trk cata- 
lytic domain. Carboxy- (C-) terminus to the catalytic domain 
resides a stretch with a length varying from a few residues up 
to 200 residues. The length and the primary structure of this 
C-terminal stretch varies among members of the Rtrk family. 
Based on sequence similarities and distinct structural charac- 





Figure 1, Structural topology of the subfamilies of receptor tyrosine kinases. Based on sequence similarities and distinct 
structural characteristics, receptor tyrosine kinases have been classified into 15 subfamilies (1,4,25,26). The abbreviations 
are defined in the text. 
  
•        Function and classification 
•        Epidermal growth factor receptor family 
The epidermal growth factor receptor (EGFR), also known as 
HER or c-ErbB, shares close sequence similarity with the trans- 
forming protein of avian erythroblastosis virus (v-ErbB) (5,6). 
The EGFR is a monomeric Rtrk. The extracellular domain is 
621 amino acids long and is characterised by the presence of 
two cysteine-rich clusters. In v-ErbB this domain is truncated, 
with only 65 amino acids at the external portion. The extra- 
cellular domain is separated from the cytoplasmic domain by 
a transmembrane region of 23 amino acids. The cytoplasmic 
domain contains an uninterrupted trk domain (Fig.l). Other 
members of the EGFR family include the p!85neu trk, also 
known as ErbB2, or HER2, ErbB3 (HERS), and ErbB4 (Tyro2)   
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(2,4). The EGFR is expressed on a variety of cell types, and 
activation of the receptor is implicated in cell proliferation 
and differentiation.  
•        Insulin receptor family 
Members of the insulin receptor family are heterotetrameric 
proteins consisting of two oc-subunits that are disulfide-linked 
to two p-subunits (Fig. 1). The extracellular ligand binding 
domain contains one cysteine-rich cluster and three fibronectin 
type III repeats. The insulin receptor is derived from a precur- 
sor which is proteolytically cleaved to yield a mature receptor 
(7,8). The CC-subunit is involved in ligand binding, whereas 
the transmembrane p-subunit contains the cytoplasmic trk 
domain. Activation of the insulin receptor induces a pleiotro- 
pic response which can be divided into metabolic and growth- 
promoting effects (9). The stimulation of metabolic effects, 
that include glucose transport, glycogen synthesis and lipid 
synthesis, is a unique characteristics of the insulin receptor. 
Mutations in the insulin receptor and defects in the postreceptor 
signaling pathways are implicated in syndromes of insulin 
resistance and may contribute to the pathogenesis of non-in- 
sulin dependent diabetes mellitus (NIDDM) (9,10). Other 
members of the insulin receptor family include the insulin- 
like growth factor-1 (IGF-1) receptor (11), the insulin recep- 
tor-related receptor (DRR), c-ros, and Ltk (2,4). Activation of 
the IGF-1 receptor also induces a pleiotropic response (12). 
Targeted disruption of the IGF-1 receptor gene causes severe 
growth deficiency and the knock out mice die at birth (13). 
•        Platelet-derived growth factor receptor family 
The platelet-derived growth factor receptors (PDGFR) are char- 
acterized by the presence of five immunoglobulin repeats in 
their extracellular domain and a cytoplasmic trk domain that 
is interrupted by a large sequence (-100 amino acids) termed 
the kinase insert region (Fig.. 1) (14). Activation of the PDGFR 
is implicated in the proliferation of mesenchymal cells. Other 
members of the PDGFR family include the macrophage-colony 
stimulating factor-1 (M-CSF-1, c-fins) receptor, the steel re- 
ceptor (SCF receptor, c-kit), and the fms-like trk 3 (flt3), also 
known as fetal liver kinase 2 (flk2) or stem cell trk 1 (stkl) 
(2,4). 
•        Fibroblast growth factor receptor family 
The extracellular domain of the fibroblast growth factor recep- 
tor (FGFR) family is composed of three immunoglobulin-like 
repeats. In addition, the extracellular domain harbours an acid 
box, consisting of eight acidic amino acids, which is located 
between the first and the second immunoglobulin domain 
(Fig. 1). The catalytic trk domain is interrupted by a small (14 
amino acids) kinase insert sequence. The prototype for the 
FGFR family, FGFR1, was originally identified as a Fms-like 
gene (Fig) (15). Subsequently, a receptor for basic FGF that was 
purified from chicken embryo, chicken embryo kinase 1 (Cekl), 
was found to be the chicken Fig product (2,4,15). Homologsfor 
Fig have been isolated from a variety of species, including 
human, mouse, and chicken (2,4,15). Other members of the 
FGFR family include FGFR2, also known as bacterial ex- 
pressed kinase (Bek), KATO-III cell-derived stomach cancer 
amplified gene (K-sam), Cek3, or TK14 (2,4), FGFR3, also 
known as Flg2 and Cek2(2,4), andFGFR4 (2,4). Mutations in 
the FGFR1, FGFR2, and FGFR3 genes are associated with au- 
tosomal dominant skeletal disorders, such as Jackson-Weiss 
syndrome, Crouzon syndrome, PfeifTer syndrome, achondropla- 
sia. hypochondroplasia, and thantophoric dysplasia. However, 
transgenic mice expressing a dominant negative form of the 
FGFR1 show a disrupted organization of keratinocytes, indicat- 
ing a role for FGFR1 in keratinocyte differentiation. 
•         Vascular endothelial growth factor receptor family 
The vascular endothelial growth factor receptor (VEGFR) fam- 
ily is highly related to the PDGFR family. The VEGFR family 
differs from the PDGFR family in that the extracellular domain 
is composed of seven immunoglobulin repeats (Fig. 1). The 
catalytic trk domain is interrupted by a large kinase insert re- 
gion in a similar way as in the PDGFR family. The first mem- 
ber of the VEGFR family that was isolated is Flt-1 (fms-like 
trk), also known as Quek-1, embryonic receptor kinase 2 
(EmRK2) (2,4). Other members of the VEGFR family include 
fetal liver kinase-1 (Flk-1), also known as KDR (2,4), and Fit- 
4, also known as Quek-2 (2,4). The VEGFR are exclusively ex- 
pressed in endothelial cells (2,4). Targeted disruption of the Flt- 
1 gene suggests an essential role for this protein in the organi- 
zation of embryonic vasculature, but not for endothelial cell dif- 
ferentiation (16). The Flk-1 gene is essential for yolk-sac blood 
island formation and embryonic angiogenesis (17). 
•        Hepatocyte growth factor receptor family 
The hepatocyte growth factor receptor (HGFR) family are 
heterodimeric proteins that are formed by proteolytic cleav- 
age of a precursor. The mature receptor consists of an entirely 
extracellular oc-subunit that is disulfide-linked to the mem- 
brane spanning P-subunit (Fig.l) (2,4). The P-subunit con- 
tains an uninterrupted trk catalytic domain. Members of the 
HGFR family include the HGFR, also known as the c-met 
proto-oncogene, the proto-oncogene c-sea, and the Ron trk 
(2,4). Activation of the HGFR is implicated in the mitogenic 
response of epithelial cells. 
Nerve growth factor receptor family 
The prototype for the nerve growth factor receptor (NGFR) is 
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trkA receptor. It is encoded by the cellular counterpart of trk 
oncogene that has originally been identified as a rearranged 
human oncogene (18 and Refs therein). The extracellular do- 
main of the NGFR family shows some homology with immu- 
noglobulin and fibronectin type III domains. In addition a leu- 
cine-rich repeat is found at the amino terminal part (Fig. 1). 
Other members of the NGFR family include trkB and trkC 
(2,4,18). trkB and trkC are both expressed as full length pro- 
teins and as C-terminal truncated receptors which have com- 
plete extracellular and transmembrane domains, but lack the 
cytoplasmic catalytic domain. Activation of the trk proteins is 
implicated in the growth, differentiation and survival of neu- 
rons (18). Mice with targeted disruption of trkA or trkC genes 
survive for a few weeks but have severe defects in the sympa- 
thetic nervous system and in muscle afferents, respectively. 
Mice lacking trkB gene die shortly after birth, apparently be- 
cause they are unable to feed. In these mice, neurons in the 
facial, trigeminal, and dorsal root ganglia, which normally 
express trkB, are not developed (2). 
• Erythropoietin-producing hepatic cell line receptor 
family 
The erythropoietin-producing hepatic cell line-like (Eph-like) 
proteins resemble the largest class of Rtrk. The prototype for 
this family is Eph proteins (2,4). The extracellular domain of 
the Eph-like proteins are composed of a cysteine-rich domain, 
and two fibronectin type III domains. The cytosolic trk domain 
is uninterrupted (Fig.l). Most members of the Eph receptor 
family, such as Elk (Eph-like kinase), also known as chicken- 
embryo kinase 6 (Cek6), Eek (Eph- and Elk-related kinase), 
Cek4, also known as mouse-embryo kinase 4 (Mek4), and 
human-embryo kinase (Hek), Cek5 (Hek5, Nuk), Sekl (Cek8, 
Hek8), Sek2, Sek3, Sek4, Eph-homologous kinase (Ehkl, 
Cek7, Hek7), Ehk2, Ehk3, mouse developmental kinase (Mdk) 
and brain-specific kinase (Bsk), are almost exclusively ex- 
pressed in the developing nervous system where they are impli- 
cated in axonal guidance (2,4). Eph, epithelial cell kinase 
(Eck), and hepatoma transmembrane kinase (Htk) show a 
broader tissue expression. Other Eph family members include 
Cek9, CeklO (Hek2) and Hekll (2,4). 
•        Axl receptor family 
The Axl subfamily of Rtrk possess extracellular domains that 
are composed of two ammo-terminal immunoglobulin-like 
domains and two fibronectin type III domains (Fig. 1). This 
combination is often observed in neural cell adhesion mol- 
ecules and receptor protein tyrosine phosphatases, and sug- 
gests an involvement of the Axl Rtrk in cell adhesion 
processes.The Axl receptor family contains distinct sequences 
in the trk domain. The prototype of the Axl family, Axl, also 
known as Ufo, Ark, was originally identified as a transform- 
ing gene from the DNA of patients with chronic myelogenic 
leukemia (2). Overexpression of Axl in NIH3T3 cells causes 
neoplastic transformation with the concomitant appearance 
of a 140 kD Axl tyrosine phosphorylated protein. Other mem- 
bers of the Axl family include c-Eyk, also known as c-Ryk. 
Rse, also known as Tyro3, Sky, Bit, or Tif, and c-Mer (2). Rse 
is expressed at high levels in the adult brain, suggesting that 
Rse may function as a novel neurotrophic receptor. c-Mer is 
almost exclusively expressed in monocytic lineages. 
•        Tie receptor family     
Members of the Tie receptor family are characterized by an 
exceptional multidomain structure of the extracellular domain, 
consisting of a cluster of three EGF homology motifs embed- 
ded between two immunoglobulin-like loops, which are fol- 
lowed by three fibronectin type III domains (Fig. 1). Members 
of the Tie family include Tie-1, also known as Tek, and Tie-2 
(2). Tie-1 and Tie-2 are specifically expressed in vascular en- 
dothelial cells during normal development and pathological 
conditions such as tumor angiogenesis. The structure of the 
extracellular domain suggests an involvement of the Tie-pro- 
teins in cell-cell adhesion in the vascular endothelium. Mice 
with a targeted disruption of the Tie-1 gene die immediately 
after birth as a result of breathing difficulties. Tie-1 ~ embryos 
fail to establish integrity of vascular endothelial cells, result- 
ing in oedema and localized haemorrhage (19). Mice with a 
targeted disruption of the Tie-2 gene die at embryonic day 
10.5 as a result of malformations in the vascular network (19). 
•        Discoidin domain receptor family 
The discoidin domain receptor (DDR) was originally identi- 
fied as a breast carcinoma phosphoprotein (2). The extracel- 
lular domain of DDR, also known as Nep, trkE, Cak, or Ptk-3, 
has homology to Dictyostelium dicoideum lectin dicoidin-I, 
and contains hydrophilic proline/glycine-rich sequences 
(Fig.l). Discoidin-I domains show homology with putative 
phospholipid-binding domains found in other cell adhesion 
molecules such as the coagulation factors V and VIII and the 
neuronal recognition protein A5. Discoidin type I domains 
are also found in Tyro 10, also known as Tkt (2). The catalytic 
domain of TyrolO exhibits significant similarity to the trk fam- 
ily of neurotrophin receptors. 
•        Ror receptor family 
Members of the Ror family (Rorl andRor2) of Rtrk were iden- 
tified by a polymerase chain reaction-based screen for new 
members of the trk family. Structural differences in the extra- 
cellular domain, which contains a cysteine-rich domain, an 
immunoglobulin-like domain, and a kringle motif (Fig.l), 
place the Ror proteins in a separate class of Rtrk (2). The D. 
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melanogaster homolog of Ror proteins (D-Ror) shows an even 
greater similarity with the catalytic domain of the trk proteins 
when compared to the human Ror proteins. Based on its neu- 
ral-specific expression pattern, it is suggested that D-Ror may 
encode a neurotrophic receptor that functions during early 
stages of neural development. 
 
•        Ret receptor family 
The Ret proto-oncogene encodes a Rtrk, in which the extra- 
cellular domain contains a sequence homologous to cadherin, 
a cell adhesion molecule (Fig.l). Germline mutations in the 
Ret gene are responsible for three different inherited cancer 
syndromes namely multiple endocrine neoplasia type 2A and 
type 2B, and familial medullary thyroid carcinoma as well as 
for Hirschsprung disease (2). Mice with a targeted disruption 
of Ret gene die shortly after birth. The knock-out mice lack 
kidneys and enteric neurons pointing to a requirement for Ret 
in organogenesis and neurogenesis (20). 
•        Ryk receptor family 
The Ryk Rtrk, also known as Nyk-r, Vik, Nbtk-1, or Mrk, (2) 
has a relatively short (-200 amino acids) extracellular domain 
(Fig.l) and some unusual substitutions at highly conserved 
residues in their catalytic domain. These substititions were 
also found in the D. melanogaster counterpart of Ryk, Droso- 
phila derailed (Drl) (2). In mice, Ryk is predominantly ex- 
pressed during hematopoietic development (2). Genetic stud- 
ies in D. melanogaster suggest an involvement for Drl in neu- 
ronal pathway recognition (2). 
•        Kinase-like gene receptor family 
The kinase-like gene (Klg) protein is a transmembrane pro- 
tein (2). The extracellular domain contains seven immuno- 
globulin-like sequences and is homologous to the VEGFR fam- 
ily (Fig. 1). As the catalytic domain lacks the highly conserved 
DFG motif, it is uncertain whether the Klg protein has intrin- 
sic trk activity 
•        Catalytic activity 
•        Ligand-induced dimerization 
Except for the insulin receptor family all Rtrk undergo a tran- 
sition from a monomeric to a dimeric state upon ligand bind- 
ing. This dimerization is inititiated through a ligand-induced 
conformational change of the extracellular domain that stabi- 
lizes interactions between adjacent cytoplasmic domains and 
leads to activation of the catalytic domain by molecular inter- 
action (1,21,22). In the case of the insulin receptor family, 
that preexists as a dimer of oc-p pairs, ligand binding presum- 
ably causes conformational changes in the preformed dimeric 
receptor that comprise an allosteric transition to yield an ac- 
tive dimer (Fig.2A) (1). 
 
Receptor dimerization can take place between two identical 
receptor molecules (homodimerization); between different 
members of the same receptor family (heterodimerization); or 
between a receptor and an accessory, coreceptor protein 
(heterodimerization). Ligand binding induces homo- or 
heterodimerization via two possible mechanisms. It may be 
mediated by simultaneous binding of a dimeric ligand to two 
receptor molecules. Examples of dimeric ligands, which thus 
contain two identical receptor-binding epitopes, include PDGF, 
CSF-1 and stem cell factor (SCF) (21). In addition to bridging 
the ligand between both receptors, direct interactions between 
the receptors involving epitopes located outside the ligand- 
binding domains may be important for stabilization of the re- 
ceptor dimer. 
A number of other growth factors such as EGF and FGF are 
monomeric in solution. A monomeric ligand binding can in- 
duce conformational changes in the receptor that stabilize its 
active dimeric form. However, evidence is emerging that both 
EGF and FGF bind to their cognate receptors in a multivalent 
manner. In the case of EGF, calorimetric studies indicate that 
a single EGF molecule can bind simultaneously to two recep- 
tor molecules (21). In the case of FGF, plasma membrane 
heparan sulfate proteoglycans act as coreceptor molecules that 
bind multiple FGF (23). In this way, FGFR dimerization is 
induced by multivalent binding of the FGF-heparan complex 
(Fig.2B) (23). 
Ligands for the Eph receptor family are all membrane an- 
chored proteins via either glycosylphosphatidylinositol or 
transmembrane domain (24). These ligands, which are inac- 
tive in soluble form, probably facilitate receptor dimerization 
by their membrane attachment. 
•        Homodimerization and heterodimerization 
The occurrence of ligand-induced homo- or heterodimerization 
provides possible means for increasing the diversity in signal- 
ing. In the case of PDGFR family, the two related PDGFR, 
PDGFRa and PDGFR(5, bind three types of dimeric PDGF 
ligands. The dimeric PDGF ligands are composed of disulphide 
linked A- or B-chains in either homodimeric (AA or BB) or 
heterodimeric (AB) combinations. The A-chain of PDGF binds 
only to a-receptors, while the B chain binds both a- and p- 
receptors with high affinity (21,22). In line with this, PDGF 
AA induces aa-receptor homodimers only, PDGF AB induces 
aa-receptor homodimers and ap-receptor heterodimers, 
whereas PDGF BB induces all three combinations of recep- 
tors (21,22). It has been observed that each receptor dimer   
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Figure 2. Models of receptor subclass-specific variations of the mechanism of activation by dimerization. (A) Allosteric 
activation of disulfide-stabilized receptor dimers. In the insulin receptor family, ligand binding results in conformational 
changes in the receptor that comprise an allosteric transition to yield an active dimer. (B) Receptor dimerization involving 
an accessory molecule. In the FGF receptor family, heparan sulfate proteoglycans in the plasma membrane act as acces- 
sory molecules that bind multiple FGF molecules. In this -way, FGF receptor dimerization and activation is induced by 
multivalent binding of the FGF-heparan sulfate proteoglycan complex. (C) Homo- and heterodimerization in the PDGF 
receptor family. The two related PDGF receptors, PDGFRa and PDGFRfi bind three types of dimeric PDGF ligands. The 
A-chain of PDGF binds only to a-receptors, -while the B-chain binds both a- and ^-receptors with high affinity. The 
repertoire of ligand specificity is increased through heterodimerization. As the cytoplasmic domains of the PDGFRaand 
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elicits specific signals with respect to the stimulation of chemo- 
taxis, actin reorganization and mitogenesis (2). Thus, the cell 
response to PDGF depends on the isoform of PDGF and the 
type of PDGFR expressed on the target cell (Fig.2C). 
Heterodimerization is also observed between members of the 
EGFR family, EGFR, ErbB2, ErbB3, and ErbB4. Ligands for 
this receptor family include EOF, transforming growth fac- 
tor-a, amphiregulin, heparin-binding EGF, betacellulin, and 
neu differentiation factor (NDF), also known as heregulin (21). 
So far, it has been reported that EGF binding induces homodi- 
merization of the EGFR (21), and heterodimerization between 
EGFR/ErbB2, and EGFR/ErbBJ (1,21,22). NDF binding leads 
to the formation of ErbB3 and ErbB4 homodimers, or ErbB2/ 
ErbB3 and ErbB2/ErbB4 heterodimers (21,22). In analogy to 
the PDGFR, the formation of homo- or heterodimers in re- 
sponse to ligands for the EGFR family results in the activa- 
tion of specific signaling pathways leading to different cellu- 
lar responses. It is interesting to note that ErbB3 lacks certain 
highly conserved amino acids in the catalytic domain (2), and 
has no kinase activity. This suggests that ErbB3 acts as a sub- 
strate for EGFR and ErbB2 in the heterodimer. 
Heterodimeriztion within an existing dimer has been noted 
between the insulin receptor and the insulin-like growth fac- 
tor-1 receptor (1). 
•        The tyrosine kinase domain 
The trk domain catalyzes the transfer of the y phosphate of a 
magnesium-adenosine triphosphate complex (Mg-ATP) to a 
protein substrate. The catalytic domains of serine/threonine 
kinases and trk are composed of-250-300 amino acids. Within 
the catalytic domain of distinct trk, sequence identities range 
from 32 to 95%. Many conserved residues in the catalytic do- 
main of trk are also conserved in the family of serine/threo- 
nine kinases (3,25,26). 
A 306-residue stretch of the insulin receptor containing the 
entire catalytic domain has been crystallized (27). The overall 
structure is similar to the structures obtained from the cata- 
lytic domain of the serine/threonine kinases cAMP-dependent 
protein kinase (PKA) (28), cyclin-dependent kinase 2, extra- 
cellular regulated kinase 2, and twitchin kinase. The catalytic 
domain is composed of two lobes that form a cleft in which 
Mg-ATP binds. It is assumed that within this cleft the protein 
substrate and Mg-ATP are brought in close vicinity to each 
other. The small amino-terminal lobe contains the highly con- 
served GlyXGlyXXGlyX(21)Lys
1030
 motif and a Glu
1047
 resi- 
due which are conserved in all protein kinases. The function 
of the glycine loop is to anchor the phosphate moiety and, in 
particular, to help position the y phosphate so that it is poised 
for transfer. In the structure of PKA, the side chains of Lys
72
 
(Lys1030 in the insmin receptor) and Glu91 (Glu1047) 
together with the side chain of Asp184 (Asp1150) in the C-
terminal lobe form a triad close to the yphosphate of Mg-ATP. 
Lys72 (Lys1030) is required for ATP-binding by interacting 
with the a and p phosphates, while Glu91 (Glu1047) and 
Asp184 (Asp1150) function inthechelation of Mg2+.  
The amino-terminal lobe is connected by a single strand to 
the large C-terminal lobe containing the principal elements of 
the active site such as the catalytic loop, the activation loop 
and the peptide-binding site. The relative orientation of the 
amino- and C-terminal lobe differs between the insulin recep- 
tor and PKA. When compared to PKA, the two lobes in the 
inactive insulin Rtrk domain are rotated away from each other. 
This orientation holds Lys
1030
, a residue in the amino-terminal 
lobe implicated in ATP-binding, at a comparatively large dis- 
tance from the catalytic residues in the C-terminal lobe. 
The catalytic loop in the C-terminal lobe is formed by the highly 










nearly invariant in both the serine/threonine kinase and trk 
families. Asp
1132
 is the catalytic base in the phosphotransfer 












) form a second 
triad of invariant amino acids implicated in Mg-ATP-bind- 




) has the potential to shuttle 
between the two conserved loops, the glycine-rich loop in the 




in PKA) provides charge neutralization. 
A marked difference between PKA and the insulin receptor is 
an extended sequence in the C-terminal lobe, termed activa- 







. The most striking fea- 
ture of the insulin receptor structure is that one of these resi- 
dues, Tyr
1162





. The phenolic ring of Tyr
1162
 points to the 









, and has an axial polar interac- 
tion with the indole ring of Trp
1175
. Together, a network of 
interactions hold Tyr
1162
 in a position that blocks access of 
ATP to the active site. This structure reveals a novel mecha- 
nism of c/5-inhibition in that residues in the activation loop of 
the unphosphorylated insulin receptor occupy the same space 
that would otherwise contain ATP. In this way, insertion of 
Tyr"
62
 represses kinase activity by precluding ATP-binding. 
From the ternary structure of the insulin receptor and PKA a 
model for insulin receptor activation has emerged. In this 
model, an equilibrium must exist between the m-inhibitory 
conformation and an "open" conformation, in which Tyr
1162
 is 
disengaged and Mg-ATP can bind. In this transient "open" 
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conformation, the kinase can be activated until Tyr
1162
 returns 
to the active site. When insulin binds to the receptor, a confor- 
mational change in the heterotetrameric receptor places the 
phosphorylation sites of one p-chain within the active site of 
the other p-chain. Intramolecular, /ra/w-phosphorylation oc- 
curs when Tyr
1162
 is disengaged andMg-ATP can bind. If phos- 
phorylation occurs on one of the tyrosine residues in the ac- 
tive site, the equilibrium shifts to a conformation in which 
Tyr
1162
 is disengaged from the active site and, as a result, the 
kinase is prone for activation (27). This model points to an 
essential role for Tyr
1162
 in insulin receptor kinase activation. 
Tyr
1162
 is a highly conserved residue in virtually all trk, and it 
is proposed that phosphorylated Tyr
1162
 is salt-bridged to the 
invariant residue Arg
1131
, and probably also Arg
1155
, thus sta- 
bilizing the non-inhibiting conformation of the active loop. 
Once activated, the kinase /raws-phosphorylates tyrosine resi- 
dues located within the cytoplasmic part of the receptor. The 
autophosphorylation of the receptor serves as a molecular 
switch to induce association and activation of cytoplasmic sig- 
naling molecules to the activated receptor. 
SIGNAL TRAMSDUCTIOH OF RECEPTOR 
TYROSINE KIHASES 
•        Protein-protein interactions 
Receptor-binding proteins all contain one or more copies of a 
protein module, termed Src homology 2 (SH2) domain, that 
directly recognize phosphotyrosine containing sequences, and 
which are responsible for the interaction of receptor-binding 
proteins with autophosphorylated receptors (29-31). In addi- 
tion to SH2 domains, recent studies have identified a second 
phosphotyrosine-binding domain, termed phosphotyrosine 
interaction domain (PID) (32). SH2 and PID mediated inter- 
actions are important for the activation of signaling pathways 
initiated by trk. Besides phosphotyrosine binding sequences, 
the substrates of Rtrk often contain distinct protein modules 
implicated in the regulation of protein-protein interactions in 
signal transduction (Fig.3). These domains include SH3 do- 
mains (29-31) and pleckstrin homology (PH) domains (33-36). 
            Src homology 2 domains 
SH2 domains have originally been described as regions of 
homology (~100 amino acids) between the non-Rtrk c-Src, c- 
Fps, and c-Abl, that lie outside the catalytic domain and are 
not required for kinase activity (29,30). Subsequently, SH2 do- 
mains have also been found in proteins that interact with acti- 
vated Rtrk, such as phospholipase Cy (PLCy), phosphatidyl- 
inositol-3'-kinase (PI3,-kinase) and p21
rai
 GTPase activating 
protein (rasGAP) (37), suggesting that SH2 domains may be 
a common feature of proteins that bind to activated Rtrk. 
Studies on the v-Crk oncogene of the avian sarcoma virus CT10 
subsequently show that the SH2 domain of v-Crk interacts with 
cellular proteins in a tyrosine phosphorylation-dependent 
manner (38). This implicates SH2 domains in the regulation 
of protein-protein interactions by recognizing peptide se- 
quences that encompass tyrosine phosphorylation sites (37). 
While SH2 domains share the common property of binding 
phosphotyrosine-containing sequences, binding specificity is 
determined by only a few amino acids located adjacent to the 
phosphotyrosine. This has been demonstrated by the differen- 
tial binding of SH2 domains of the p85a subunit of PI3,-ki- 
nase, rasGAP and PLCyto activated growth factor receptors 
(39,40). Peptide competition and receptor mutagenesis experi- 
ments reveal that 3-5 amino acids C-termini to the phosphoty- 
rosine are sufficient to capture the essential elements of se- 
quence-specific recognition (40). 
The ternary structure of the SH2 domains of several proteins 
has clarified the mechanisms of phosphotyrosine and peptide 
recognition (41). The ternary structures of the Src, Lck, PLCy, 
and SH-PTP2 SH2 domains complexed with phosphotyrosine 
containing peptides (42,43,44), and the solution structures of 
the SH2 domains of the p85a subunit of PI,,-kinase (45) and 
c-Abl (46) in absence of bound ligands has been resolved. The 
obtained ternary structures are strikingly similar and share a 
common secondary structure framework and considerable simi- 
larity in ternary folding. In the ternary structure, the amino- 
and C-terminal ends of the SH2 domains are close together in 
a globular structure, allowing the SH2 domain to protrude from 
the rest of the protein, and function independently. ; 
The SH2 domain is composed of two a-helices, termed aA 
and aB, and seven p-strands, termed PA through PG, located 
in the order appppppapp (47). The spine of the Src SH2 
domain is an uninterrupted p-meander that forms two distinct 
p-sheets. The sheets are connected by a single continuous p- 
strand, termed PD, in the central p-sheet and PD' in the sec- 
ond. The central three-stranded antiparallel P-sheet (strands 
PB, pC. PD) divides the SH2 domain into two distinct sides. 
One side, containing a-helix a A and one face of the central 
P-sheet, is primarily involved in phosphotyrosine binding. The 
other side of the SH2 domain, containing a-helix aB, the 
smaller P-sheet (strands PD', PE, pF), a long loop termed BG, 
and the other side of the central P-sheet. is implicated in the 
binding of three peptide residues C-termini to the phosphoty- 
rosine. The peptide recognition site runs along a flat surface 
perpendicular to the central P-sheet, whereas the phosphoty- 
rosine is contained in a pocket located on this surface. 
The interactions in the phosphotyrosine pocket are very simi- 
lar between the Lck and Src complex (43,44). The side chain 
of the phosphotyrosine lies in a deep, elongated groove formed 
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Figure 3. Modular structure of receptor-binding proteins and other proteins involved in signal transduction. The functions 
and abbreviations of the distinct domains and of the proteins depicted are outlined in the text. 
  
by parts of the PB, PC, and PD strands, the aA helix, and the 
BCloop ("phosphate-binding" loop). Several highly conserved 
residues in this pocket interact directly with the bound 
phosphotyrosine. The side chains of HispD4 and LyspD6 and 
the main-chain atoms of TyrpD5 form a platform beneath the 
aromatic ring of the phosphotyrosine. The phosphate moiety 
is held by a network of hydrogen bonds, in which two argin- 
ine residues are of particular importance. ArgocA2 donates 
four hydrogen bonds to the phosphotyrosine peptide: one to 
the phosphate oxygen, one amino-aromatic bond to the 
phosphotyrosine ring, and two to the main chain carbonyl of 
pY-1. This arginine residue is therefore critical for the con- 
formation of the entire phosphotyrosine residue. The second 
arginine residue ArgpB5 makes bidentate hydrogen bonds with 
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Besides the conserved phosphotyrosine binding pocket, the 
structural data indicate that SH2 domains also possess a pocket 
for the 3-6 amino acids residues C-termini to the phosphoty- 
rosine. In contrast to the phosphotyrosine binding site, this 
pocket is lined by variable residues, and hence allows different 
SH2 domains to bind preferentially to distinct residues C-ter- 
mini to the phosphotyrosine. The binding specificities of SH2 
domains have been determined in detail by comparing the bind- 
ing sites of SH2 domains and by incubation of SH2 domains 
with degenerate phosphotyrosine containing peptides (48,49). 
Based on these studies and the identity of amino acid pD5 in the 
SH2 domain, SH2 domains have been divided into several 
categories (48,49). 
Group I SH2 domains have a Phe or Tyr at the PD5 position 
and recognize sequences with the general motif phosphoty- 
rosine-hydrophilic-hydrophilic-hydrophobic (48,49). Members 
of this group include the 8112 domains of the Src family of 
non-Rtrk, of rasGAP and growth factor receptor-bound pro- 
tein 2 (GRB2). Upon binding of the Src or Lck SH2 domain, 
the hydrophobic residue at the +3 position (He or Pro) is al- 
most completely buried at the hydrophobic binding site. The 
hydrophilic residues at positions +1 and +2 lie along the sur- 
face of the SH2 domain (43,44). 
The SH2 domain in Vav, a guanine nucleotide exchange fac- 
tor for ras, recognizes the same motif as group ISH2 domains, 
though the presence of a Thr residue at the PD5 position places 
Vav in group II (49). 
Group III SH2 domains, having He or Cys at the PD5 posi- 
tion, select sequences with the general motif phosphotyrosine- 
hydrophobic-X-hydrophobic, though the individual members 
of this group select unique sequences (48,49). Members of 
this group include the SH2 domains of the p85oc and p85 P 
subunit of PI3,-kinase, PLCy, the SH2 domain containing 
phosphotyrosine phospatases SH-PTP1, SH-PTP2, and Csw, 
and the She protein (48,49). This group of SH2 domains pri- 
marily binds phosphopeptides at the +1 and +3 positions rela- 
tive to the phosphotyrosine. In addition to the C-terminal resi- 
dues, evidence is emerging that also residues amino-termini 
to the phosphotyrosine may be involved in sequence specific 
binding of some SH2 domains. 
 
To date, SH2 domains have been identified in many proteins, 
that include enzymes, adaptors, structural proteins, and tran- 
scription factors. The binding of activated Rtrk to SH2 do- 
main-containing proteins provides a mechanism for recruit- 
ing substrates and targets to activated Rtrk dimers. 
                           Phosphotyrosine interaction domains 
In addition to SH2 domains, a distinct PID, also known as 
She and IRS-1 NPXY-binding domain (SAIN), has been iden- 
tified in several proteins, including the adapter protein She, 
and the insulin receptor substrates (ERS), IRS-1 and IRS-2 
(32,50-52). PID domains appear to be structurally unrelated 
to SH2 domains and recognize specifically tyrosine phospho- 
rylated NPXY motifs (50-52). The average length of the PID 
domain is about 160 amino acids. Structure predictions sug- 
gest that PK) domains are globular, and the arrangement of 
a-helices and p-strands indicates the presence of an antipar- 
allel p-sheet (32). Sequence alignments have shown that PID 
domains share a hydrophobicity pattern and conserved mo- 





 in She. One conserved motif located in the ammo-ter- 
minal region of the PID domain is reminiscent of the con- 
served FLVRES-motif found in SH2 domains which is criti- 
cal for the interaction with phosphotyrosine-containing pep- 
tides. Deletion of the FLVRES-like element in the Pro do- 
main of She entirely eliminates the binding of She to tyrosine 
phosphorylated NPXY motifs (50). 
•        Src homology 3 domains 
Src homology 3 (SH3) domains are stretches of 55-70 amino 
acids in length that have been first identified as regions of 
homology between PLCy, v-Crk, and Src (29,30,37). SH3 do- 
mains are now known to be widely distributed among proteins 
involved in signaling pathways (29,30,37). The crystal struc- 
tures of the SH3 domains of oc-spectrin (53) and c-Fyn (54), 
and the solution structures of the SH3 domains from c-Src 
(55), PI3,-kinase (56), and PLCy (57) have been resolved. De- 
spite characteristic differences between the individual SH3 
domains, the general structure of the SH3 domains is con- 
served. Like SH2 domains, SIC domains have a globular struc- 
ture in which the amino- and C-terminal ends are close to- 
gether. This allows the SH3 domains to exist as an indepen- 
dent entity in proteins with minimal disruption of the sur- 
rounding structure. The spine of the SH3 domain is formed by 
two antiparallel p-sheets packed together at approximately 
right angles. The interface of the sheets forms a hydrophobic 
core composed of several highly conserved residues. The hy- 
drophobic pocket may serve as a binding site for target pro- 
teins. 
A number of SH3 domain-binding proteins have been identi- 
fied, and subsequent sequence comparisons have led to the 
recognition that a short proline-rich peptide motif of approxi- 
mately 10 amino acids binds to SH3 domains (58). Screening 
of combinational libraries of proline-rich peptides identify two 
classes of peptides as ligands for Src and PL,-kinase SH3 do- 
mains (59): class I ligands have a consensus sequence 
RXLPPZP (Z=L for Src SH3; Z=R for PI3,-kinase SH3), and 
class II ligands contain a XPPLPXR motif. Structural studies 
of SH3 domains complexed with proline-rich ligands indicate 
  
Ouwens and Maassen 14 
Biomed Rev 5,1996 
Insulin receptors and related protein tyrosine kinases 
  
that the bound ligands adopt a left-handed polyproline type II 
helix (59). In this helix, two prolines interact directly with the 
surface of the SH3 domain. Other prolines contribute to the 
formation of the helix, whereas the non-proline residues, con- 
sisting of combinations of arginine and leucine, interact ex- 
tensively with the SH3 domain and apparently confer ligand 
specificity. Remarkably, structures of ligand-bound SH3 do- 
mains reveal that SH3 domains bind class I ligands in an ori- 
entation that is opposite to that observed for bound class II 
ligands (59). This indicates that activation of SH3 domain- 
mediated pathways does not only depend on the subset of se- 
quences bound by the SH3 domain, but also on the correct 
orientation required for the assembly of an active signalling 
complex.  
•        Pleckstrin homology domains 
The pleckstrin homology (PH) domain is a sequence of ap- 
proximately 120 amino acids homologous to two regions of 
pleckstrin which is the major PKC substrate in platelets. This 
region of homology is frequently found in many proteins in- 
volved in signaling pathways (33-36). More than 70 PH domain 
containing proteins have been identified, including serine/ 
threonine kinases, trk, severeal isoforms of PLC, GAP, nucle- 
otide exchange factors, adaptors, and cytoskeletal proteins (33- 
36)  
PH domains are implicated in intramolecular interactions in 
signaling pathways. This notion has emerged from the find- 
ing that a naturally occurring mutation in the PH domain of 
Bruton's tyrosine kinase (Btrk) is sufficient to cause the hu- 
man genetic disease agammaglobulinaemia. Moreover, in vivo 
functional analysis of the D. melanogaster guanine nucleotide 
exchange factor son of sevenless (SOS) revealed that the PH 
domain is essential for the development of the D. melanogaster 
eye. 
The crystal structure for the PH domain of dynamin and the 
solution structure of the PH domains of spectrin, pleckstrin 
and dynamin has been determined (60,61). The basic struc- 
ture of the molecule is an antiparallel p-sheet consisting of 
seven p-strands, with a long a-helix at the C-terminus. The 
p-sheet has a strong bend, that is stabilized by the a-helix 
packing. Opposite this helix are three loops that vary among 
most PH domains. The overall structure of the PH domain is 
electrostatically polarized, with the three variable loops form- 
ing a positively charged surface that may serve as a ligand 
binding site. This positively charged surface includes the po- 
sition of mutation in the Btrk PH domain. 
The structure of the PH domain shows similarity to the struc- 
ture of lipid-binding proteins. A characteristic shared by all 
PH domain-containing proteins is the functional importance 
of membrane localization (33-36,60). In line with a putative 
membrane targeting role for PH domains, fusion proteins con- 
taining PH domains of several proteins bind specifically to the 
negatively charged phospholipid phosphatidyl-inositol-4,5- 
biphosphate (62). In these experiments, the ammo-terminus 
of the PH domain has been identified as the important site of 
lipid interaction. In addition to lipid binding, the PH domain 
of the p-adrenergic receptor kinase-1 has been demonstrated 
to bind to the Gpy subunits of heterotrimeric G proteins (60). 
This interaction is mediated by the C-terminus of the PH do- 
main (60). Both PH domain-binding ligands are neccessary 
for membrane association and activation of the kinase (60). 
The requirement for the simultaneous presence of two PH do- 
main-binding ligands represents a novel mechanism for ef- 
fecting membrane localization of a protein and may have rel- 
evance to other PH domain-containing proteins. 
•        Substrates of receptor tyrosine kinases 
The binding of cytoplasmic signaling molecules to autophos- 
phorylated Rtrk provides a mechanism for recruiting substrates 
and targets to activated Rtrk dimers. The receptor-binding pro- 
teins all contain one or more copies of SH2 or PDD domain 
that directly recognizes the phosphotyrosine-containing bind- 
ing sites in the autophosphorylated receptor. 
The specificity in signaling is provided by sequence specific 
recognition of phosphotyrosine-containing sequences by SH2 
and PID domains, though appears to be ultimately determined 
by the catalytic specificity of the trk. Using a degenerate pep- 
tide library, with peptides with the sequence Met-Ala-XXXX- 
Tyr-XXX-Ala-Lys-Lys as a substrate, the substrate specificity 
of trk has been investigated (63). Most trk select peptides with 
Glu or Asp residues at the -4 to -2 positions relative of the 
Tyr. Rtrk also prefer a Glu at the -1 position, while the non- 
Rtrk preferentially phosphorylate tyrosine residues preceded 
by an lie or Val. The selectivity for residues C-termini to the 
Tyr is strikingly similar to the phosphopeptide motifs recog- 
nized by SH2 domains. All trk show a selection for hydropho- 
bic residues at the +3 position. Rtrk phosphorylate a general 
motif Tyr-hydrophobic-X-hydrophobic, a sequence generally 
recognized by group III SH2 domains as found in the p85 sub- 
unit of PI3,-kinase, PLCy, and SH-PTP2 (48,49). In contrast, 
non-Rtrk show a preference for Tyr-hydrophilic-hydrophilic- 
hydrophobic, a sequence recognized by group ISH2 domains 
(48,49). 
As described earlier, SH2 and Pro domains are found in many 
proteins. Based on their structural properties, the receptor- 
binding proteins have been classified into distinct classes (29). 
The first class of receptor-binding proteins is formed by pro- 
teins with known enzymatic activity. The binding of the en- 
zymes to the receptor can facilitate efficient tyrosine phospho- 
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rylation leading to activation of the enzyme, or may induce 
allosteric activation of the bound enzyme. Members of this 
class include PLCy, rasGAP, SH2 domain containing protein 
tyrosine phosphatases, and non-Rtrk. The second class of re- 
ceptor-binding proteins, termed adaptors, are devoid of any 
enzymatic activity. These proteins are often composed of SH2 
and SH3 domains, and function as intermediates between Rtrk 
and downstream signaling molecules. Members of the adap- 
tors family include the p85 subunit of PI3,-kinase, GRB2, Crk, 
Nek, and She. Docking proteins represent the third class of 
receptor-binding proteins. They have no enzymatic activity, 
but act as an Rtrk surrogate by providing multiple SH2 do- 
main binding sites following tyrosine phosphorylation by an 
activated Rtrk. Members of this class include IRS-1 and IRS- 
The recruitment of SH2 or PID domain-containing proteins to 
activated Rtrk or to a tyrosine phosphorylated docking protein 
represents the first step in the activation of signaling cascades. 
The best characterized signaling pathways in fibroblasts initi- 
ated by activated Rtrk are described below. 
•        Activation of the p21"" signaling pathway 
The p2 1 "" genes are the cellular counterparts of the transform- 
ing genes of the Harvey and Kirsten strains of rat sarcoma vi- 
rus, and of the transforming gene of a neuroblastoma cell line. 
The products of the p21™ genes are small GTP-binding pro- 
teins of approximately 21 kD localized at the inner side of the 
plasma membrane. By analogy to other GTP-binding proteins, 
p2 1 "" cycles between an inactive GDP-bound state and an ac- 
tive GTP-bound state (Fig. 4) (64-66). In the oncogenic forms 
of p21
TO
 which have been detected in a variety of human tu- 
mors, point mutations at positions 12, 13 or 61 lock the pro- 
tein in a constitutively activated GTP-bound state (67). 
Genetic evidence from D. melanogaster and C. elegans, mi- 
croinjection studies with neutralizing antibodies and overex- 
pression of p21
ras
 proteins in fibroblasts have placed p21"* in 
signal transduction downstream of Rtrk (2). A wide variety of 
growth factors increase the intracellular levels of p21""-GTP 
(2). Moreover, cells expressing oncogenic forms of trk such as 
v-Src, v-Abl, oiv-ErbB2 also exhibit increased levels ofp21
ral
- 
GTP (2).  
The p2 1 "* guanine nucleotide content can be regulated at two 
levels. First, at the level of exchange of GDP for GTP by gua- 
nine nucleotide exchange factors (GNEF) (Fig.4). Second, at 
the level of hydrolysis of p21""-GTP, a process catalyzed by 
GTPase activating proteins (GAP) (64-66,68) (Fig.4). Evidence 
has been obtained that growth factors enhance the exchange 
rate of GDP-bound to p21
ray
 by exogeneous guanine nucle- 
otides, indicating an involvement of GNEF in the formation 
of p21™-GTP (69,70). Based on homology with the catalytic 
domain of S. cerevisiae and D. melanogaster GNEF for ras 
(cdc25 and SOS protein, respectively), several putative mam- 
malian GNEF have been identified, including mSOS (71). 
Despite the cloning of GNEF, the mechanism by which acti- 
vated trk couple to p21"" remains unclear, though the identifi- 
cation of the GRB2 protein contributes to the elucidation of 
the activation mechanism.  
GRB2 was originally identified by screening a protein expres- 
sion library with the autophosphorylated C-terminal tail of the 
EGFR and by screening a cDNA library with degenerate oli- 
gonucleotides recognizing SH2 domains (72). GRB2 encodes 
a 23 kD protein that is devoid of any enzymatic function and 
consists almost entirely of two SH3domains separated by one 
SH2 domain. Genetic counterparts for GRB2 have been iso- 
lated from C. elegans (Sem-5; sex muscle abnormal) and D. 
melanogaster (Drk; downstream of receptor kinases) (73-75). 
GRB2 associates through its SH2 domain to tyrosine phos- 
phorylated phosphotyrosine-hydrophilic-hydrophilic-hydro- 
phobic sequences with a strong preference for Asn at the +2 
position (49). Many activated Rtrkbind GRB2 directly, though 
in some cases the binding of GRB2 requires an adaptor pro- 
tein, such as She, SH-PTP2, RPTPoc, IRS-1 or IRS-2 (2). An 
involvement of GRB2 in the regulation of p21"" comes from 
the observation that overexpression of GRB2 enhances the 
activation of p21"
K
 by EGF (76) and the activation of ERK2 
by insulin (77). Moreover, coinjection of GRB2 together with 
P21™
1
 leads to the induction of DNA synthesis in quiescent 
fibroblasts, while injection of GRB2 or p21
rai
 alone has no 
effect (72). Also genetic evidence from C. elegans places GRB2 
in a pathway upstream of p21"". GRB2 is the mammalian ho- 
mologue of the C. elegans Sem-5 (73). In C. elegans, the in- 
duction of vulval differentiation is regulated by the Let-23 trk 
and the Let-60 ras protein. Mutation of the Sem-5 allele abro- 
gates vulval development, and experimental evidence places 
Sem-5 downstream of Let-23 and upstream of Let-60 (73). 
Genetic analysis of the D. melanogaster Drk protein suggests 
that Drk function is essential for signaling of the sevenless 
Rtrk that mediates proper specification of the R7 photorecep- 
tors in the D. melanogaster eye (74,75). In these studies, the 
biological activity of Drk correlates with the binding of the 
Drk SHE domain to the activated sevenless receptor and con- 
comitant localization to the plasma membrane. A major break- 
through in the investigation of the mechanism for linking trk 
to p21
rai
 is the finding that Drk SH3 domains bind in vitro to 
proline-rich sequences in the C-terminal tail of SOS (74,75). 
SOS is a D. melanogaster guanine nucleotide exchange factor 
which is, like ras and Drk, required for sevenless signaling 
(71). 
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Figure 4. Regulation ofp21
ras
guanine nucleotide content by receptor tyrosine kinases. Upon ligand induced activation of 
receptor tyrosine kinase, She can bind to phosphotyrosine residues within the activated receptor. The activated receptor 
tyrosine kinase induces tyrosine phosphorylation of She which is followed by the association ofGRB2. Alternatively, GRB2 
can bind directly to an activated receptor tyrosine kinase. The SH3 domain ofGRB2 is bound to the C-terminal tail of 
mSOS.   The interaction of GRB2/mSOS with phosphotyrosine residues probably induces a conformational change that 
relieves the inhibitory constraint of the C-terminal tail ofmSOS. In this way, active mSOS can promote the exchange of 




-GTP is inactivated by hydrolysis ofGDP to GTP which is catalyzed by GTPase activating 
proteins (GAP).     
  
Subsequently, it has been demonstrated that GRB2 binds to 
the mammalian homolog of SOS (mSOS) and that this com- 
plex exists constitutively (78-82). From this result, it has been 
proposed that the binding of the GRB2/mSOS complex to an 
activated Rtrk translocates mSOS to the vicinity of membrane- 
bound p21"". As a result of this translocation,the exchange of 
GDP for GTP on p2l™ may be stimulated (Fig.4). 
In vivo structure-function analysis of SOS reveals that the 
amino-terminus of SOS is essential for its function in D. 
melanogaster. The amino-terminal region contains a PH do- 
main which is implicated in membrane binding. In line with 
this membrane recruitment model, modified mSOS proteins 
that are constitutively located at the plasma membrane acti- 
vate the p2l"" signaling pathway without external stimuli. 
These membrane-targeted mSOS derivatives are even more 
active upon deletion of the C-terminal region, the binding site 
for the GRB2 SH3 domains. This suggests that a secondary 
activation mechanism may rely on a conformational change 
induced by binding of GRB2/mSOS to tyrosine phosphory- 
lated proteins that relieves the inhibitory effect of the C-ter- 
minal domain of mSOS (Fig. 4). 
Besides interacting with activated Rtrk, the 8112 domain of 
GRB2 also binds to tyrosine phosphorylated Src-homology 
collagen (She) (83). The primary structure of She contains an 
amino-terminal PID domain and a C-terminal SH2 domain 
separated by a glycine/proline-rich motif with regions of ho- 
mology to the a,-chain of collagen (50,51,83). She has been 
implicated in p21"* activation, since its overexpression trans- 
forms cells and induces p21 ""-dependent neurite outgrowth 
(83,84). She interacts with several activated Rtrk through its 
PID and/or SH2 domain (2), and as a result She becomes ty- 
rosine phosphorylated. Tyrosine phosphorylated She associ- 
ates with GRB2/mSOS (84) (Fig.4). This interaction is pre- 
sumably mediated by the binding of the GRB2 SH2 domain to 
a tyrosine phosphorylated YVNV motif within the She pro- 
tein. In this way, the interaction of tyrosine phosphorylated 
She with GRB2/mSOS provides an alternative mechanism for 
the activation of the p21"
K
 signaling pathway by Rtrk. 
 
         Effectors of p21™         
Activated p21
OT
 exerts its effects by interacting with one or 
more cellular effector molecules. Mutations in p21™ which 
abrogate its biological activity without reducing GTP-binding 
have delineated a domain in p21™ that associates with effec- 
tor molecules, termed effector domain, to a region between 
amino acids 35-40. Among the proteins that physically inter- 
act with the effector domain in a GTP-dependent manner are   
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neurofibromin, Raf , PL,-kinase, a ral guanine dissociation 
stimulator, and a ral guanine dissociation stimulator-like pro- 
tein (85). 
The interaction of activated P21"* with Raf leads to the acti- 
vation of a set of cytoplasmic serine/threonine kinases, includ- 
ing Raf itself, MAP-ERK-kinase (MEK), ERK1/2 and 90 kD 
S6 kinase (86). Neurofibromin and rasGAP catalyze the hy- 
drolysis of activated p21"*. The interaction of these proteins 
with pll"" is implicated in the negative regulation of p21
rai
, 
though may also serve a role as effector. The interaction of 
p21"* with PI3,-kinase may contribute to the activation of this 
enzyme. Ral guanine dissociation stimulator is a GNEF for 
the ras family member ral, though the role of the interaction 
between p21 "* and ral guanine dissociation stimulator remains 
to be clarified. 
•        Activation of the Raf/MEK/ERK pathway 
As described above, GTP-bound p21"" interacts with the 
amino-terminal domain of the serine/threonine kinase Raf (87- 
89). However, p21
ras
-GTP does not stimulate the kinase activ- 
ity of Raf in vitro (88). Furthermore, purified active Raf is not 
associated with p21
rar
 and thus appears to be locked into the 
active state through a covalent modification, or through high- 
affinity interaction with an unknown regulator (90). This raises 
the possibility that p21"" functions as a regulated, membrane- 
bound anchor to recruit Raf to the plasma membrane. Indeed, 
modified Raf proteins that associate with the plasma mem- 
brane are constitutively active, and under these circumstances 
independent of pll™ (91,92). 
However, several lines of evidence point to an involvement of 
additional factors in the activation of Raf. First, growth fac- 
tors can further activate membrane-bound Raf via a mecha- 
nism independent of P21"" (91). This suggests that other ki- 
nases are required for full activation and phosphorylation of 
Raf. Second, once deposited to the plasma membrane, Raf 
becomes associated with structural elements as it cannot be 
released from the plasma membrane with detergent (92). These 
components are expected to contain the missing link that lock 
Raf in its kinase-active state. 
A putative group of proteins that may contribute to Raf activa- 
tion are members of the family of 14-3-3 proteins. The 14-3-3 
P and 14-3-3 £ isoforms interact with both the amino-termi- 
nal and the kinase domain of Raf, though without interfering 
with the binding of Raf to p21™-GTP (90). 14-3-3 proteins 
associate with Raf in mammalian cells and accompany Raf to 
the plasma membrane during the process of activation. More- 
over, both 14-3-3 (3 and 14-3-3 £ activated Raf in vitro, thus 
suggesting that 14-3-3 proteins may participate in or be re- 
quired for activation of Raf.  
Cells transformed with v-Raf, or the oncogenic mutants of c- 
Raf, display elevated MEK activity, suggesting that MEK, also 
known as MAP kinase kinase, is downstream of Raf (93). A 
MEK gene isolated from D. melanogaster acts as a down- 
stream suppressor of Raf providing genetic evidence that Raf 
functions upstream of MEK (86). MEK is a family of dual- 
specificity protein kinases which activate ERK1 and ERK2 by 
phosphorylation of threonine and tyrosine residues. Raf im- 
munoprecipitates can activate MEK in vitro by phosphoryla- 
tion of serine residues 218 and 222 (94,95) (Fig.5). Other up- 
stream activators of MEK are the mammalian homologue of 
the yeast STE11 gene, MEK kinase, and the proto-oncogene 
c-mos, a germ cell specific serine/threonine kinase (86). 




 leading to activation of ERK (86). ERK comprises 
a family of serine/threonine kinases (96). In contrast to Raf 
and MEK, ERK appears to have multiple substrates, includ- 
ing phospholipase A2, 90 kD S6 kinase, the transcription fac- 
tors myc, fun, Elk-1, and PHAS-I (96). ERK also phosphory- 
lates mSOS which may represent a negative feedback of the 
p21™VERK pathway (97). 
•         Activation of the JNK/SAPK and other MAPK pathways 
In addition to the p21 ""/Raf/MEK/ERK pathway, several MAP 
kinase (MAPK)-related pathways have been characterized 
(Fig.5). These pathways are regulated by a three-component 
protein kinase cascade consisting of a serine/threonine pro- 
tein kinase (MAPKKK), which phosphorylates and activates 
a dual-specificity kinase (MAPKK) that in turn activates an- 
other serine/threonine kinase (MAPK). The MAPK serve to 
link signals from the plasma membrane to the cytosol and the 
nucleus, and are implicated in the regulation of cell shape, 
osmotic integrity, and pheromone responses in yeast, stress 
responses in mammalian cells, and cytokine signaling (96). 
In mammalian cells, at least three MAPK-related families exist, 
including the jun N-terminal/stress-activated protein kinase 
(JNK/SAPK), /bs-regulating kinase (FRK), andMAPKAPki- 
nase-2 reactivating kinase (RK/MPK2/p38 ) (96). These sub- 
groups are distinguished by the sequence of the tripeptide dual 
specificity phosphorylation motif that is required for activa- 
tion: Thr-Glu-Tyr (ERK), Thr-Pro-Tyr (JNK/SAPK), andThr- 
Gly-Tyr (RK/MPK2/p38). 
The JNK/SAPK family comprises several isoforms, the human 
46 kD JNK1 and 54 kD JNK2 protein, and the rat p54a, p54p, 
and p54y SAPKs (98). JNK/SAPK are potently activated in 
response to cellular stress, ultraviolet radiation, incubation with 
protein synthesis inhibitors, genotoxic agents, interleukin-1 
and tumor necrosis factor-a (TNF-a), and to a lesser extent by 
oncogenic p21
OT
, EOF andNGF. The activation of JNK/SAPK 
by EOF and by NGF depends on p21"", whereas JNK/SAPK ac- 
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tivation by TNF-a is p21
TO
-independent (96,98). JNK/SAPK 
binds to the ammo-terminal transactivation domain of the tran- 
scription factors c-jun and ATF-2, and phosphorylates serines 
63 and 63 of c-jun and threonines 69 and 71 of ATF-2 (96,98). 
The phosphorylation of ATF-2 and c-jun is implicated in tran- 
scriptional activation of these proteins. 
SAPK/ERK kinase-1 (SEK-1), also known as JNK kinase 
(JNKK or MKK4), a dual-specificity protein kinase structur- 





of JNK/SAPK in vitro and in vitro leading to activation of 
JNK/SAPK, whereas an inactive SEK-1 mutant blocks JNK/ 
SAPK activation by extracellular stimuli (96,98). In addition 
to SEK-1, Q-sepharose chromatography of cells exposed to 
hyperosmolar media indicate the existence of another activa- 
tor of JNK/SAPK. 
SEK-1 on its turn is activated through phosphorylation by 
MEKK (96,98). MEKK, a serine/threonine kinase structur- 
ally related to Raf, has originally been identified as activator 
of MEK, though this activation occurs only in vitro or upon 
overexpression of MEKK (86). When expressed at physiologi- 
cal levels, no MEK activation can been seen. In analogy to 
Raf, MEKK is activated by small GTP-binding proteins. Con- 
stitutively active mutants of Racl and Cdc42 are efficient ac- 
tivators of the kinase cascade leading to JNK/SAPK activa- 
tion (99,100). Studies with dominant negative mutants iden- 
tify Racl as an intermediate between P21"* and MEKK in 
Rtrk signaling toward JNK/SAPK (99,100). 
The pathway leading to RK/MPK2/p38 activation is highly 
related to the pathway regulating JNK/SAPK (Fig.5). Like 
JNK/SAPK, RK/MPK2/p38 is activated in response to cellu- 
  
 
Figure 5. MAP kinase pathways in mammalian cells. MAP kinase pathways in mammalian cells contain a central core of 
GTP-binding protein, a serine/threonine kinase (MAPKKK), a dual-specificity kinase (MAPKK) and a serine/threonine 
kinase (MAPK). The activation of the ERK pathway is implicated in proliferation and differentiation, while JNK/SAPK and 











lar stress, such as heat shock or osmotic stress, and by 
interleukin-1 (98). The activation of RK/MPK2/p38 leads to 
activation of MAPK-activated protein kinase-2 (MAPKAP 
kinase-2) which subsequently phosphorylates small heat shock 
proteins (98). Activation of RK/MPK2/p38 is mediated by 




 motif. RK/MPK2/p38 
is specifically activated by the dual-specificity kinase MKK3 
(98). Also SEK-1 activates RK/MPK2/p38 in vitro, though 
coexpression of SEK-1 and its activator MEKK does not lead 
to a marked activation of RK/MPK2/p38 (98). This implicates 
a novel uncharacterized MEKK related protein kinase in the 
regulation of the RK/MPK2/p38 kinase cascade. Upstream of 
the MEKK-related protein kinase lies the small GIF-binding 
proteins Racl and Cdc42 (99,100). 
Other putative p21 ""-dependent MAPK pathways include FRK 
(96), which phosphorylates the transactivation domain of Fos, 
and an unidentified kinase responsible for the phosphoryla- 
tion of CREB in response to NGF (96). 
•        p21
ras
 GTPase activating proteins        
GTPase activating proteins (GAP) catalyze the hydrolysis of 
p21""-bound GTP. p21™* GTPase activity is stimulated by the 
rasGAP protein (Fig.4). Two cDNAs encoding rasGAP have 
been identified, type 1 GAP (-120 kD) and type 2 GAP (-100 
kD) (101,102). Type 2 GAP lacks the first 180 amino acids 
due to alternative splicing, though the protein is active with 
respect to stimulation of p21
r<
" GTPase activity. The primary 
structure of rasGAP contains some intriguing domains. The 
C-terminal 400 amino acids contain the catalytic domain that 
is neccessary for the interaction with p21
raj
. In the amino- 
terminus, half of the protein resides a stretch of two 8112 do- 
mains separated by one SH3 domain. The SH2-SH3-SH2 do- 
main sequence is separated from the catalytic domain by a PH 
domain. 
Genetic evidence from D. melanogaster and S. cerevisiae in- 
dicates that rasGAP functions as a negative regulator of p21 
r
<*. 
Overexpression of rasGAP in fibroblasts suppresses focus for- 
mation and morphological transformation induced by p21
n
", 
v-Src. and v-Fms. Inhibition of rasGAP activity or of its inter- 
action with p21"* may result in elevation of p21'
m
-GTP levels. 
Indeed, activation of the T cell receptor leads to inhibition of 
overall rasGAP activity, and may thus contribute to p21
r<
"- 
GTP formation (103). 
The SH2 domains of rasGAP are implicated in the interaction 
of rasGAP with activated Rtrk, including PDGFR, EGFR, in- 
sulin receptor, and HGFR (2). Upon this association, rasGAP 
becomes tyrosine phosphorylated and associates with two other 
phosphoproteins, p62 and p!90 (104). Cells expressing mu- 
tant PDGFR that lack rasGAP binding site, display normal 
p21ras-GTP formation, suggesting that this interaction is not 
involved in the process (40). 
Although rasGAP has been purified as a negative regulator 
for p21"*, rasGAP may also contribute positively to signaling. 
Expression of the SH2-SH3-SH2 stretch of rasGAP inhibits 
opening of K* channels in atrial cell membrane, and induces 
the expression of c-fos promoter-driven luciferase gene 
(105,106). The effector functions of rasGAP may involve the 
formation of a complex between rasGAP and p62 and pi90 
(104). p62 shows homology with a putative hnRNP protein 
(GRP33), and recombinant p62 binds to RNA and DNA in 
vitro, suggesting a role for p62 in RNA and DNA metabolism 
(107). p!90 that binds to the SH3 domain of rasGAP has a 
region homologous n-chimerin and rho-GAP (108). It has been 
shown that p 190 has GTPase activity toward Rho, a small GTP- 
binding protein implicated in actin stress fiber formation (109), 
and that expression of the rasGAP SH2-SH3-SH2 stretch and 
association with pi90 correlates with changes in the 
cytoskeleton and reduces cell adhesion to fibronectin (110). 
•        Phosphatidylinositol 3-kinase 
Interest in lipid kinases is first sparked by the observation that 
phosphatidylinositol kinase (Pl-kinase) activity associates with 
several retrovirally encoded oncogenes, including v-Src, and 
polyomavirus middle T antigen (2). This observation leads to 
the identification of two Pl-kinases in fibroblasts (2). Type I 
Pl-kinase, generally known as PI3,-kinase, phosphorylates the 
D3 position in the inositol ring of PI and PI(4)P, whereas type 
II or PI4-kinase phosphorylates PI on the D4 position. 
PI3,-kinase purified from brain or liver exists as a heterodimer 
composed of a 85 kD regulatory subunit (p85), and a 110 kD 
catalytic subunit (pi 10). pi 10 is a dual-specificity kinase. It 
has intrinsic PI3,-kinase activity in the absence of the regula- 
tory p85 subunit. In addition to the lipid kinase activity, pi 10 
has an associated Mn
2+
-dependent protein kinase activity that 
can phosphorylate a specific serine, Ser
608
, in the p85 subunit, 
resulting in inhibition of PI3,-kinase activity (111). The cata- 
lytic domain of pi 10 is distantly related to a family of protein 
kinases involved in cell cycle control, DNA damage response 
and repair (112). The amino-terminal domain of pi 10 is in- 
volved in the interaction with the p85 subunit. This domain is 
less conserved or even absent in pi 10-related kinases (112). 
The regulatory p85 subunit of PI3,-kinase functions as an adap- 
tor linking tyrosine phosphorylated Rtrk to PIy-kinase activa- 
tion (113). The primary sequences of p85 a and p85 [3 isoforms 
reveal a multidomain structure containing a number of non- 
catalytic domains. At the amino-terminus of the protein lies a 
SH3 domain followed by a region with significant sequence 
homology to the product of the breakpoint cluster region (BCR)   
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gene. This region of BCR has GTPase-activating activity to- 
ward the small GTP-binding protein Rac (113). The C-termi- 
nal half of the molecule is dominated by two SH2 domains 
(113). The region between the SH2 domains contains the bind- 
ing site for pi 10 subunit (113). Ser
608
 which is phosphory- 
lated by pi 10 subunit is located in this region and is impli- 
cated in the regulation of PI3,-kinase activity (111). In addi- 
tion, the p85 subunit contains two binding sites for SH3 do- 
mains (2). Binding of SH3 domains of non-Rtrk to purified 
PI3,-kinase leads to activation of the enzyme (2). The SH2 do- 
mains of the p85 subunit mediate the binding of PI3,-kinase to 
phosphotyrosine residues in activated Rtrk or in so-called adap- 
tor molecules, such as IRS-1 and IRS-2 (2). The p85 SH2 do- 
mains recognize a tyrosine phosphorylated YXXM motif (48), 
and both SH2 domains are required for stable binding. The 
association between Rtrk and p85 subunit is stimulated by nu- 
merous growth factors, and results in allosteric activation of 
theholoenzyme. 
The involvement of active PI3,-kinase and 3'-phosphoinositide 
metabolites in cellular signaling is studied with receptor mu- 
tants that lack PI3,-kinase binding sites, with mutant p85 pro- 
teins that lack the pi 10 binding site, and using the specific in- 
hibitors of PI,, -kinase activity. From these studies, evidence has 
been obtained that PI3,-kinase may lie on the pathway leading 
to cell proliferation (40,114,115). Furthermore, activation of 
PI,,-kinase is apparently required for insulin, IGF-1, HGF, and 
PDGF (2). This observation fits with a role for PI3,-kinase in Rac 
activation, a protein regulating membrane ruffling (113). 
Despite evidence for an involvement of PI3,-kinase in several 
cellular processes, relatively little is known about the mecha- 
nisms that transmit the signal beyond this pointRecently, a 
putative target of 3'-phosphoinositides has been characterized. 
Evidence indicates that the 60 kD serine/threonine kinase Akt, 
also known as PKB or Rac, lies on a pathway downstream of 
PI,,-kinase (116): (/') activation of Akt by growth factors is 
inhibited by wortmannin, a specific inhibitor of PI,, -kinases, 
(ii) PDGFR mutants that fail to activate PI3,-kinase also fail to 
activate Akt/PKB, (Hi) a dominant negative mutant of PI,,- 
kinase inhibits PDGF activation of Akt/PKB, and (iv) phospha- 
tidylinositol-3-monophosphate (PtdIns3P), but not Ptdlns or 
PtdIns(4,5)P2, can activate Akt/PKB in vitro. Activation of 
Akt/PKB is inhibited by mutations in the amino-terminal PH 
domain (116). As this domain is essential for protein homo- 
dimerization, it is tempting to speculate that binding of 3'- 
phosphoinositides to the PH domain can promote dimeriza- 
tion of Akt/PKB and so activate it, possibly by inducing pro- 
tein autophosphorylation. 
Among the potential targets of Akt/PKB is the 70 kD S6 ki- 
nase. p70 S6 kinase is activated by constitutively active Akt/ 
PKB in vivo (116). In addition, growth factor induced activa- 
tion of p70 S6 kinase is inhibited by PI3,-kinase inhibitors 
(117,118). However, PDGFR mutants that fail to activate PI3,- 
kinase and Akt/PKB still activate p70 S6 kinase (117,118), 
suggesting that several pathways contribute to the activation 
of this enzyme (118). 
•        Phospholipase Cy 
Activation of phospholipase Cy (PLCy) induces the hydroly- 
sis of phosphatidylinositol 4,5-diphosphate (PIP2) to diacyl- 
glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG 
is the physiological activator of PKC, whereas IP, mobilizes 
Ca
2+
 from intracellular stores, thereby affecting Ca
w
-depen- 
dent intracellular processes. 
The primary structure of PLCy, which is similar in its two 
known isoforms (PLCyl and PLC y2), contains two central SH2 
domains and a SH3 domain C-terminus to the central SH2 
domain. This SH2-SH2-SH3 structure is flanked by a split PH 
domain. The SH2 domains of PLCy direct the interaction with 
activated Rtrk. Both SH2 domains belong to group III that 
bind phosphotyrosine-hydrophobic-X-hydrophobic sequences, 
though the amino- and the C-terminal SH2 domain display 
different binding specificities (48). The amino-terminal SH2 
domain preferentially binds to the sequence phosphotyrosine- 
Ile/Leu/Val-acidic (Glu/Asp)-Ile/Leu/Val, while the C-termi- 
nal SH2 domain binds the sequence phosphotyrosine-Val/Ile- 
hydrophobic (Ile/Leu)-Pro/Ile/Val. The SH3 domain localizes 
PLCy to the cytoskeleton (119). The significance of the split 
PH domain remains to be clarified.  
Most but not all activated Rtrk bind PLCyl (2). Binding of 
PLCyl to the activated Rtrk apparently facilitates the tyrosine 
phosphorylation of PLCyl. Both binding and tyrosine phos- 
phorylation of PLCyl are essential for its activation. Studies 
with mutant FGFR and PDGFR that lack PLCyl binding sites 
indicate that activation of PLCyl per se is not required for the 
induction of DNA synthesis (2). However, restoration of Tyr
1021
, 
the PLCyl binding site in PDGFR, partially restores DNA syn- 
thesis (114). This indicates that activation of PLCy itself can 
induce a mitogenic response. 
•       Protein tyrosine phosphatases 
Protein tyrosine phosphatases (FTP) represent a diverse fam- 
ily of enzymes that catalyze the dephosphorylation of phospho- 
tyrosine residues in activated Rtrk and their substrates. PTP 
can be divided into two groups. One group comprises recep- 
tor-like PTP, that contain a putative extracellular ligand bind- 
ing domain, a transmembrane domain and a highly conserved 
cytoplasmic catalytic domain (120,121). The other group is 
formed by a large expanding family of cytoplasmic PTP 
(120,121). Within the family of cytoplasmic PTP, two PTP   
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have been characterized that contain SH2 domains, termed 
SH-PTP1 and SH-PTP2 (120,121). 
The primary structure of SH-PTP1, also known as FTP 1C, 
SHP, and HCP, indicates the presence of two amino-terminal 
SH2 domains and a C-terminal catalytic domain (122). The 
expression of SH-PTP1 is limited to lymphocytes. The amino- 
terminal SH2 domain of SH-PTP1 recognizes a broad selec- 
tion of phosphotyrosine-hydrophobic-X-hydrophobic se- 
quences with a slight preference for Phe at the +1 and +3 
position relative to the phosphotyrosine (49). The optimal bind- 
ing motif for the C-terminal SH2 domain has not been deter- 
mined yet. The amino-terminal SH2 domain of SH-PTP1 as- 
sociates in vitro with tyrosine phosphorylated EOF and SCF 
receptors (122). Expression of SH-PTP1 in 293 cells induced 
a partial or complete dephosphorylation of the EGFR, ErbB2, 
overexpressed PDGFRoc and PDGFRp, and the P subunits and 
unprocessed precursors of the insulin and IGF-1 receptor (123). 
No direct interaction between CSF-1 receptor and SH-PTP1 
could be demonstrated (2). Despite this, SH-PTP1 has been 
identified as a tyrosine phosphorylated protein in macroph- 
ages incubated with CSF-1 (2). In vivo, SH-PTP1 is probably 
involved in attenuation of the mitogenic response in macroph- 
ages, as macrophages isolated from mice homozygous for the 
motheaten locus, which encodes the SH-PTP1 gene, show CSF- 
1 independent proliferation (2). 
SH-PTP2, also known as PTP1D, PTP2C, Syp, or SH-PTP3, 
has a primary structure similar to SH-PTP 1 (123). The amino- 
terminal SH2 domain recognizes phosphotyrosine-hydropho- 
bic-X-hydrophobic sequences with a small preference for He or 
Val at the +1 position, and a Val, lie, Leu, or Pro at the +3 
position (48). In response to growth factor stimulation, SH- 
PTP2 associates to activated growth factor receptors through its 
SH2 domains, becomes tyrosine phosphorylated and thus lead- 
ing to increased FTP activity (2,123). For full activation of the 
enzyme, the interaction of both SH2 domains with phosphop- 
roteins is required. In contrast to what is found for SH-PTP 1, 
SH-PTP2 does not dephosphorylate the cytoplasmic domains of 
EFGR, ErbB2, PDGFRoc, PDGFRP, insulin and IGF-1 recep- 
tors (123). The main tyrosine phosphorylation site in SH-PTP2 
has been mapped to Tyr
542
 (124). This tyrosine lies in the con- 
sensus binding motif (YTNI) for the SH2 domain of GRB2, 
which by association with mSOS couples Rtrk to the activation 
of p21
r<M
. In response to PDGF stimulation, tyrosine phospho- 
rylated SH-PTP2 acts as an adapter between PDGFR and 
GRB2-mSOS complex (125), suggesting that SH-PTP2 maybe 
an upstream component in the activation of p21"". Indeed, res- 
toration of the SH-PTP2 binding site in a PDGFR mutant lack- 
ing all the tyrosine autophosphorylation sites, is sufficient for 
full activation of p21
ras
 hi response to PDGF (114), whereas ex- 
pression of a dominant negative mutant of SH-PTP2 attenuates 
insulin-induced activation of p21
rat
/ERK pathway (126,127). 
•        Non-receptor tyrosine kinases 
•        Src-like tyrosine kinases 
The prototype of Src-like trk family, c-Src, is the cellular ho- 
mologue of the transforming protein of Rous sarcoma virus (v- 
Src). Members of this family of non-Rtrk include c-Src itself, 
c-Yes, Fyn, Lyn, and Lck. All Src-like trk contain a Gly resi- 
due at position 2 which is required for myristylation and mem- 
brane attachment. The first 70-80 amino acids of the amino- 
terminus are unique among the members of Src-like trk. This 
stretch is followed by a SH3 domain and a SH2 domain. The 
C-terminal half of the protein contains the catalytic domain and 
a regulatory tyrosine phosphorylation site (128). 
The trk activity of c-Src is increased by dephosphorylation of 
the C-terminal tyrosine residue, Tyr
527
 (128). Mutation of this 
tyrosine increases trk activity and transforming potential of 
Src. The kinase activity of c-Src is negatively regulated by 
phosphorylation of Tyr
527
, presumably by C-terminal Src ki- 
nase (Csk) (129). The negative regulation of Src by phospho- 
rylation involves the binding of Src SH2 domain to the phos- 
phorylated Tyr
527
, thus leading to steric hinderence of the cata- 
lytic domain (128).  
The activity of Src and Src-related kinases is increased after 
stimulation of fibroblasts with PDGF or CSF-1, and during 
mitosis (130). So far, several substrates for Src have been char- 
acterized, including paxillin, focal adhesion kinase, pi 10, 
p!30, PI3,-kinase, and src-associated in mitosis 68 kD (Sam68) 
(2,129). 
•        Focal adhesion kinase  
Focal adhesion kinase (pp!25
FAK
) is a cytosolic trk which is 
predominantly localized to focal adhesions (131,132). Its struc- 
ture reveals a central catalytic domain flanked by large amino- 
and C-terminal sequences that are devoid of SH2 and SH3 
domains (131,132). The amino-terminal non-catalytic se- 
quence binds to the cytosolic part of the p-integrin subunit 
(133). The C-terminal stretch of pp!25
FAK
 contains the focal 
adhesion targeting sequence (FAT) which is neccessary for its 
localization to focal adhesions. The C-terminus also contains 
binding sites for two other focal adhesion-associated proteins, 
talin and paxillin (133).  
pp!25
FAK
 is tyrosine phosphorylated in response to cellular 
adhesion and subsequent integrin clustering and after stimu- 
lation of cells with polypeptide growth factors and mitogens 
(133). Tyrosine phosphorylation of tyrosine 397 of pp!25
FAK 
facilitates the SH2 domain directed binding of c-Src and Fyn, 
resulting in activation of these enzymes (134). Activation of 
c-Src is implicated in the phosphorylation of other tyrosine   
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residues within pp!25FAK, thus enhancing the enzymatic ac- 
tivity of pp!25FAK (133). In addition, activation of pp!25FAK 
and c-Src induces the tyrosine phosphorylation of focal adhe- 
sion-associated proteins like paxillin, p!30 and tensin (133). 
The tyrosine phosphorylation of these proteins is implicated 
in the formation of focal adhesions (133-135).  
 
INSULIN RECEPTOR SIGNALING 
•        The insulin receptor 
The insulin receptor is a member of Rtrk family. While most 
Rtrk elicit a mitogenic response, the insulin receptor also in- 
duces a metabolic response like stimulation of glucose uptake 
and glycogen synthesis. Upon insulin binding, the insulin re- 
ceptor undergoes tyrosine phosphorylation starting at Tyr1138 
and one of the two vicinal Tyr1162 and Tyr1163. The phosphory- 
lation of the three major tyrosine autophosphorylation sites 
increases the phosphotransferase activity of trk. In addition to 
phosphorylation of the triple tyrosines in the kinase domain, 
minor tyrosine phosphorylation occurs at position 972 in the 
juxtamembrane domain, and at positions 1328 and 1344 in 
the C-terminal tail (136-138). 
Following receptor autophosphorylation and concurrent recep- 
tor activation, several substrate proteins become tyrosine phos- 
phorylated. These proteins include IRS-1, IRS-2 and She (52, 
139,140). The tyrosine phosphorylation of these proteins con- 
tributes to the activation of postreceptor signaling pathways that 
lead to the various cellular responses mediated by insulin. 
•        Postreceptor signaling 
Insulin receptor is among the Rtrk that stimulate the forma- 
tion of p21 ras-GTP (141). This involves a GNEF that enhances 
the rate of guanine nucleotide binding on p21"* (70). Several 
studies point to an involvement of She in this process (142- 
144). She binds directly via its PID domain to the activated 
insulin receptor, thus facilitating tyrosine phosphorylation of 
She (50,140). This tyrosine phosphorylation is followed by 
the binding of She to GRB2/mSOS (143). The formation of a 
multiprotein complex between the activated insulin receptor, 
She, GRB2, and mSOS brings mSOS in the vicinity of mem- 
brane-bound p2lras. As a result, the exchange of GDP for GTP 
on p21OT is stimulated. The activation of p2r<K is followed by 
activation of Raf, MEK and ERK as described earlier in this 
review. 
Tyrosine phosphorylation of TRS-1 and IRS-2 is an unique 
response of the insulin receptor family, although some mem- 
bers of the cytokine receptor family also induce this response 
(52). IRS-1 and IRS-2 are cytoplasmic proteins, which con- 
tain at least 22 potential tyrosine phosphorylation sites and 
two domains involved in protein-protein interactions, e.g. PH 
and PID domains (52,139). The tyrosine phosphorylation of 
IRS-1 and presumably IRS-2 directs the binding of several 
SH2 domain-containing proteins, including the p85 subunit 
of PI3,-kinase, SH-PTP2, GRB2, and Nek (9). The binding of 
p85 subunit to tyrosine phosphorylated TRS-1 reflects the main 
step in insulin-Induced activation of PI3,-kinase (9). Regard- 
ing GRB2, several lines of evidence have indicated that p21™- 
GTP formation can proceed independently of TRS-1/GRB2 
complex formation (142-144). 
The requirement of p21 ™ and PI3, -kinase for insulin-stimulated 
glucose uptake and glycogen synthesis has been investigated. 
Activation of the p21 ""/ERK pathway alone appears not to be 
sufficient to stimulate glucose transport in 3T3L1 adipocytes 
(145). The involvement of this pathway has been subsequently 
exluded by expression of a dominant negative mutant of p21ras, 
p2i"z,(ASNi7) jhis p2i^ mutant abrogates the signaling path- 
way mediated by endogeneous p21""-GTP (146), but has no 
effect on insulin-stimulated glucose uptake and glycogen syn- 
thesis (147). In contrast, insulin-mediated glucose uptake and 
glycogen synthesis is completely abolished by wortmannin, an 
inhibitor of PI3,-kinase (115,147). This suggests that PI3,-ki- 
nase, or another wortmannin-sensitive enzyme, is an essen- 
tial intermediate in insulin-induced metabolic signaling. 
Insulin receptor activation also promotes the tyrosine dephos- 
phorylation of pp!25FAK and paxillin (148,149). The dephos- 
phorylation of pp!25FAK requires phosphotyrosine residue 1158 
in the activated insulin receptor and is accomplished by acti- 
vation of PTP ID (149,150). pp!25FAK dephosphorylation by 
insulin is accompanied by a reduction in the amount of cyto- 
solic stress fibres, though the physiological relevance of this 
event remains to be identified (150). 
 
CONCLUSIONS 
• In the last decade, considerable progress has been made 
towards the understanding of Rtrk signaling pathways. Ligand 
binding induces dimerization, activation and autophospho- 
rylation of the Rtrk. The autophosphorylated tyrosine residues 
form binding sites for proteins containing SH2 or PID do- 
mains. The recruitement of these proteins to the receptor rep- 
resents the first step in the activation of postreceptor signal- 
ing pathways. The specificity in signaling is probably achieved 
by identity of the proteins that bind to a specific Rtrk as well 
as tissue-specific expression of substrates. 
Although a number of early postreceptor signaling pathways 
has been elucidated by now, their contribution to cellular re- 
sponses remains to be clarified. In case of the insulin receptor, 
the elucidation of signaling pathways that are involved in the 
regulation of glucose uptake and glycogen synthesis may con-   
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tribute to the identification of candidate genes involved in the 
pathogenesis of NIDDM. 
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